Bio Techne Corp Stock Today

TECH Stock  USD 70.39  0.97  1.40%   

Performance

0 of 100

 
Low
 
High
Very Weak

Odds Of Distress

Less than 9

 
100  
 
Zero
Low
Bio Techne is trading at 70.39 as of the 29th of March 2024. This is a 1.40 percent increase since the beginning of the trading day. The stock's open price was 69.42. Bio Techne has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Bio Techne Corp are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of February 2024 and ending today, the 29th of March 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
9th of February 1989
Category
Healthcare
Classification
Health Care
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota. The company has 157.19 M outstanding shares of which 5.1 M shares are at this time shorted by private and institutional investors with about 4.7 trading days to cover. More on Bio Techne Corp

Moving against Bio Stock

  0.48CLVRW Clever Leaves HoldingsPairCorr
  0.42FGEN FibroGen Financial Report 13th of May 2024 PairCorr

Bio Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Bio Techne's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Bio Techne or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEO and President and DirectorCharles Kummeth
Old NameTechfinancials Inc
Business ConcentrationLife Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP 500 Index, Dow Jones Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Life Sciences Tools & Services, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering Bio Techne report their recommendations after researching Bio Techne's financial statements, talking to executives and customers, or listening in on Bio Techne's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Bio-Techne Corp. The Bio consensus assessment is calculated by taking the average forecast from all of the analysts covering Bio Techne.
Bio Techne's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Bio Techne's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Bio Techne's financial leverage. It provides some insight into what part of Bio Techne's total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Bio Techne's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Bio Techne deploys its capital and how much of that capital is borrowed.
Liquidity
Bio Techne cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 454.96 M in liabilities with Debt to Equity (D/E) ratio of 0.19, which may suggest the company is not taking enough advantage from borrowing. Bio-Techne Corp has a current ratio of 3.37, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Bio Techne until it has trouble settling it off, either with new capital or with free cash flow. So, Bio Techne's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bio-Techne Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bio to invest in growth at high rates of return. When we think about Bio Techne's use of debt, we should always consider it together with cash and equity.

Free Cash Flow

261 Million
Bio Techne Corp (TECH) is traded on NASDAQ Exchange in USA. It is located in 614 McKinley Place N.E., Minneapolis, MN, United States, 55413 and employs 3,200 people. Bio Techne is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 10.91 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bio Techne's market, we take the total number of its shares issued and multiply it by Bio Techne's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Bio-Techne Corp conducts business under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 157.19 M outstanding shares of which 5.1 M shares are at this time shorted by private and institutional investors with about 4.7 trading days to cover. Bio Techne Corp currently holds about 247.03 M in cash with 254.39 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.3.
Check Bio Techne Probability Of Bankruptcy
Ownership Allocation
Bio-Techne Corp retains a total of 157.19 Million outstanding shares. The majority of Bio Techne Corp outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Bio-Techne Corp to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Bio Techne. Please pay attention to any change in the institutional holdings of Bio Techne Corp as this could imply that something significant has changed or is about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.
Check Bio Ownership Details

Bio Stock Price Odds Analysis

Coming from a normal probability distribution, the odds of Bio Techne jumping above the current price in 90 days from now is about 71.14%. The Bio Techne Corp probability density function shows the probability of Bio Techne stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.8123. This usually implies as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Bio Techne will likely underperform. Additionally, bio Techne Corp has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming NYSE Composite.
  Odds Below 70.39HorizonTargetOdds Above 70.39
28.61%90 days
 70.39 
71.14%
Based on a normal probability distribution, the odds of Bio Techne to move above the current price in 90 days from now is about 71.14 (This Bio Techne Corp probability density function shows the probability of Bio Stock to fall within a particular range of prices over 90 days) .

Bio Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Bio Techne that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Bio Techne's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bio Techne's value.
InstituionRecorded OnShares
T. Rowe Price Associates, Inc.2023-12-31
M
Amvescap Plc.2023-12-31
M
Champlain Investment Partners, Llc2023-12-31
2.8 M
Macquarie Group Ltd2023-12-31
2.5 M
Bank Of New York Mellon Corp2023-12-31
2.5 M
Mackenzie Investments2023-12-31
2.4 M
Marshall Wace Asset Management Ltd2023-12-31
2.3 M
William Blair Investment Management, Llc2023-12-31
2.2 M
Ameriprise Financial Inc2023-12-31
M
Vanguard Group Inc2023-12-31
18.2 M
Blackrock Inc2023-12-31
18.1 M
View Bio Techne Diagnostics

Bio Techne Historical Income Statement

Bio Techne Corp Income Statement is one of the three primary financial statements used for reporting Bio's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Bio-Techne Corp revenue and expense. Bio Techne Income Statement primarily focuses on the company's revenues and expenses during a particular period.
As of now, Bio Techne's Other Operating Expenses is increasing as compared to previous years. The Bio Techne's current Operating Income is estimated to increase to about 361 M, while Interest Expense is forecasted to increase to (12.3 M). View More Fundamentals

Bio Stock Against Markets

Picking the right benchmark for Bio Techne stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Bio Techne stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Bio Techne is critical whether you are bullish or bearish towards Bio Techne Corp at a given time. Please also check how Bio Techne's historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Bio Techne without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Alpha Finder Now

   

Alpha Finder

Use alpha and beta coefficients to find investment opportunities after accounting for the risk
All  Next Launch Module

Bio Techne Corporate Directors

Bio Techne corporate directors refer to members of a Bio Techne board of directors. The board of directors generally takes responsibility for the Bio Techne's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Bio Techne's board members must vote for the resolution. The Bio Techne board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Roeland NusseIndependent DirectorProfile
Charles DinarelloIndependent DirectorProfile
Joseph KeeganDirectorProfile
Rupert VesseyIndependent DirectorProfile

How to buy Bio Stock?

Before investing in Bio Techne, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Bio Techne. To buy Bio Techne stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Bio Techne. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Bio Techne stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Bio Techne Corp stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Bio Techne Corp stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Bio Techne Corp, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Bio Stock please use our How to Invest in Bio Techne guide.

Already Invested in Bio Techne Corp?

The danger of trading Bio Techne Corp is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Bio Techne is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Bio Techne. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Bio-Techne Corp is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Bio-Techne Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Techne's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Techne Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Techne Corp Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Bio Techne Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
Note that the Bio-Techne Corp information on this page should be used as a complementary analysis to other Bio Techne's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.

Complementary Tools for Bio Stock analysis

When running Bio Techne's price analysis, check to measure Bio Techne's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Techne is operating at the current time. Most of Bio Techne's value examination focuses on studying past and present price action to predict the probability of Bio Techne's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Techne's price. Additionally, you may evaluate how the addition of Bio Techne to your portfolios can decrease your overall portfolio volatility.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Is Bio Techne's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Techne. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Techne listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.45)
Dividend Share
0.32
Earnings Share
1.39
Revenue Per Share
7.263
Quarterly Revenue Growth
0.004
The market value of Bio-Techne Corp is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Techne's value that differs from its market value or its book value, called intrinsic value, which is Bio Techne's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Techne's market value can be influenced by many factors that don't directly affect Bio Techne's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Techne's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Techne is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Techne's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.